Abstracts tagged "Activity score"

Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker ², Sandy Hong ³, Polly Ferguson ⁴, Themba Nyrienda ⁵, Tracy Andrews ⁶, Katie Stewart ⁷, C. Egla Rabinovich ⁸, Robert Fuhlbrigge ⁹, Thomas Mason ¹⁰, Elena Pope ¹¹, Maria Ibarra ¹², Fatma Dedeoglu ¹³, Gloria Higgins ¹⁴, Ronald Laxer ¹⁵, Marilynn Punaro ¹⁶ and Kathryn Torok ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ³University of Iowa Stead Family Children's Hospital, Iowa City, ⁴University of Iowa Carver College of Medicine, Iowa City, ⁵Hackensack Univesity Medical Center, Hackensack, ⁶Rutgers University, Newark, ⁷UT Southwestern, Dallas, ⁸Duke University Hospital, Durham, ⁹University of Colorado, Aurora, ¹⁰Rochester, ¹¹Hospital For Sick Kids, Toronto, Canada, ¹²Children's Mercy Kansas City, Kansas City, ¹³Boston Children's Hospital, Boston, ¹⁴Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁵The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁶Dallas, Texas, ¹⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
Britney Jones¹, Bo Pan ¹, Joanne Homik ², Anthony Russell ², Walter P. Maksymowych ³, Jill Hall ¹ and Stephanie Keeling ¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, Canada, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…
Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting
Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
MASAOMI YAMASAKI¹, ¹Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
Abstract Number: 744 • 2018 ACR/ARHP Annual Meeting
Association of PCSK9 Serum Levels with Lipid Metabolism Dysregulation, Activity/Damage Scores and Subclinical Atherosclerosis in SLE Patients
Hiurma Sanchez-Perez¹, Juan Carlos Quevedo², Iñigo Rua-Figueroa³, Beatriz Tejera-Segura⁴, De Vera-González AM⁵, Alejandra Gonzalez-Delgado⁶, Federico Díaz-González⁷ and Iván Ferraz-Amaro⁸, ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology, Hospital Doctor Negrin, Las Palmas GC, Spain, ³Division of Rheumatology, Hospital Doctor Negrín, Las Palmas, Spain, ⁴Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, ⁵Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁶Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, ⁷Reumatología, Servicio de Reumatología, Hospital Universitario de Canarias,Spain, La Laguna, Spain, ⁸Division of Rheumatology.Hospital Universitario de Canarias, Tenerife, Spain
Background/Purpose: Cardiovascular disease is one of the major causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). SLE patients are characterized by…
Abstract Number: 766 • 2018 ACR/ARHP Annual Meeting
Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
Laura Patricia Whittall¹, Diana Gómez-Martín¹, Jiram Torres-Ruíz², Alejandro Zentella Dehesa¹, Miguel Tapia-Rodríguez¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Current evidence suggests that neutrophils play an important role in the pathophysiology of lupus nephritis (LN) mainly through the secretion of type I IFN…
Abstract Number: 1096 • 2018 ACR/ARHP Annual Meeting
Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus
Laurent Chiche¹, julie seguier², stephanie gentile², stephane burtey², bertrand dussol², philippe halfon³, wahiba bidaut³, elisabeth jouve² and Noémie Jourde-Chiche⁴, ¹Internal medicine, Hopital europeen, Marseille, France, ²aphm, marseille, France, ³hopital europeen, marseille, France, ⁴Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France
Background/Purpose: SLE has important effects on health-related quality of life (HRQOL) and is not well correlated to disease activity. As most SLE patients in remission…
Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
Min-Hua Tseng¹ and Jing-Long Huang², ¹Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Medicine, Chang-Gung University, Taoyuan city, Taiwan
Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…
Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 2667 • 2018 ACR/ARHP Annual Meeting
Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
Manuel Ugarte-Gil^1,2, Ines Segami^3,4, Guillermina Harvey⁵, Guillermo J. Pons-Estel⁶, Rosana Quintana⁷, Cristina Reategui-Sokolova⁸, Jorge Cieza⁴, Luis J. Catoggio⁹, Mercedes Garcia¹⁰, Verónica Saurit¹¹, Francisco Caeiro¹², Cristina Drenkard¹³, Guillermo Berbotto¹⁴, Emilia Sato¹⁵, Lilian Costallat¹⁶, Eloisa Bonfa¹⁷, Joao C. Tavares Brenol¹⁸, Nilzio A Da Silva¹⁹, Fernando Cavalcanti²⁰, Antonio Iglesias-Gamarra²¹, Marlene Guibert-Toledano²², Gil A. Reyes²², Loreto Massardo²³, Oscar J Neira²⁴, Mario H Cardiel²⁵, Leonor Barile²⁶, Mary Carmen Amigo²⁷, Luis H. Silveira²⁸, Ignacio Garcia de la Torre²⁹, Eduardo Acevedo-Vasquez², Rosa Chacón-Díaz³⁰, Maria H Esteva Spinetti³¹, Graciela S. Alarcón^32,33 and Bernardo A Pons-Estel⁷, ¹Rheumatology, Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁴Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, ⁵Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ⁸Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁹Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ¹¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹²Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹³Medicine/Rheumatology, Emory University, Atlanta, GA, ¹⁴Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁵Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹⁶Universidade Estadual da Campinas, Campinas, Brazil, ¹⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹⁸Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, ¹⁹Faculdade de Medicina da Universidade Federal de Goiás, Goiania, Brazil, ²⁰Universidade Federal da Pernambuco, Pernambuco, Brazil, ²¹Universidad Nacional de Colombia, Bogota, Colombia, ²²Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, ²³Centro de Biología Celular y Biomedicina (CEBICEM), Universidad San Sebastián, Santiago, Chile, ²⁴Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ²⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ²⁶Hospital Ángeles del Pedregal, Mexico, Mexico, ²⁷Rheumatology, Centro Medico ABC, Mexico, Mexico, ²⁸Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ²⁹Hospital General de Occidente, Guadalajara, Mexico, ³⁰Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ³¹Hospital Central de San Cristóbal, San Cristobal, Venezuela (Bolivarian Republic of), ³²Universidad Peruana Cayetano Heredia, Lima, Peru, ³³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose,…
Abstract Number: 463 • 2018 ACR/ARHP Annual Meeting
Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
Pooja Patel¹, Marietta M. De Guzman¹, Joseph Maliakkal², Michelle Rheault³, David Selewski⁴, Katherine Twombley⁵, Jason Misurac⁶, Cheryl Tran⁷, Alexandru Constantinescu⁸, Ali Mirza Onder⁹, Meredith Seamon¹⁰, Vaishali Singh¹¹, Cynthia Pan¹¹, Joseph Flynn¹², Abiodun Omoloja¹³, William Smoyer¹⁴, Guillermo Hidalgo¹⁵ and Scott E. Wenderfer¹⁶, ¹Pediatrics-Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatrics-Renal, Saint Louis University, St. Louis, MO, ³Pediatrics-Renal, University of Minnesota, Minneapolis, MN, ⁴Pediatrics-Renal, University of Michigan, Ann Arbor, MI, ⁵Pediatrics-Renal, Medical University of South Carolina, Charleston, SC, ⁶Pediatrics-Renal, University of Iowa, Iowa City, IA, ⁷Pediatrics-Renal, Mayo Clinic, Rochester, MN, ⁸Pediatrics-Renal, Joe DiMaggio Children’s Hospital, Hollywood, FL, ⁹Pediatrics-Renal, University of Tennessee, Memphis, TN, ¹⁰Pediatrics-Renal, The University of Utah, Salt Lake, UT, ¹¹Pediatrics-Renal, Medical College of Wisconsin, Wauwatosa, WI, ¹²Pediatrics-Renal, Seattle Children's Hospital, Seattle, WA, ¹³Pediatrics-Renal, Wright State University, Dayton, OH, ¹⁴Pediatrics-Renal, Nationwide Children’s Hospital, Columbus, OH, ¹⁵Pediatrics-Renal, East Carolina University, Greenville, NC, ¹⁶Pediatrics-Renal, Baylor College of Medicine, Houston, TX
Background/Purpose: Outcomes for childhood-onset crescentic lupus nephritis are unclear. The revised classification system for lupus nephritis by the Renal Pathology Society clearly distinguishes between cellular,…
Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Genki Kidoguchi¹ and Kenichiro Tokunaga², ¹General internal medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan
Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…
Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
Adeeba Al-Herz¹, Khulood Saleh², Adel Al-Awadhi³, Waleed Al-Kandari², Eman Hasan⁴, Aqeel Ghanem⁵, Yaser Ali⁵, Hebah Alhajeri⁶, Sawsan Hayat⁵, Ali Aldei⁷, Mohammad Hussain⁴, Ibrahim Nahar⁵, Fatemah Abutiban⁸, Ahmad Alenizi⁸, Khaled Mokaddem¹, Ahmad Khadrawy², Ammad Fazal², Agaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁸ and Ahmed Al-Saber⁹, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Farwania Hospital, Farwania, Kuwait, ³Faculty of Medicine, Kuwait, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, ⁷Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, ⁸Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁹Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting
How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Laura C. Coates², Ana-Maria Orbai³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Laure Gossec²², ¹Sorbonne Université, PARIS, France, ²University of Oxford, Oxford, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Sorbonne Universités, Paris, France
Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting
Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
Yair Molad^1,2, Mohammad Egbaria³, Ariela Dortort-Lazar^4,5, Elisheva Pokroy-Shapira^3,5, Shirly Oren⁴, Yonatan Edel^3,5 and Vitaly Kliminski^5,6, ¹Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, ²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁴Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].